Azercabtagene zapreleucel (“azer-cel”) is an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T cell therapy. In contrast to autologous CAR T cell therapies which are made individually from a patient’s own cells, azer-cel is an allogeneic or “off-the-shelf” therapy made from donor-derived T cells, modified using a proprietary genome editing technology. Azer-cel recognizes the well characterized B cell surface protein CD19 and is designed to avoid graft-versus-host disease, a significant complication associated with other donor-derived, cell-based therapies.